Dr Noelle Sunstrom, CEO, NeuClone
Sydney-based molecular biologist Dr Noelle Sunstrom is at the forefront of a relatively new industry that will put biologics in the hands of more patients globally. Through her biopharmaceutical company NeuClone, Sunstrom and her team are developing and commercialising high-quality biosimilars using proprietary technology developed in Australia.
Originally from Canada, Sunstrom obtained a PhD from McGill University in Montreal before moving to Australia on a post-doctoral scholarship with the John Curtin School of Medical Research at the Australian National University.
She began her academic research career at the University of New South Wales, where she led a team in producing monoclonal antibody drug therapies for the influenza virus, collaborating with big pharma in taking those drugs to market. She and her team developed cutting-edge ways to produce complex biopharmaceuticals for commercial production.
In 2000, Sunstrom co-founded Acyte Biotech, which commercialises intellectual property from the mammalian cell research groups at the University of New South Wales and University of Queensland.
She completed an Executive MBA in 2007 and soon after founded NeuClone. Sunstrom is also a Fellow of the Australian Institute of Company Directors and the Royal Society of New South Wales.
Read Dr Noelle Sunstrom Profile
Read Media Release